Quick Answer
Cadrenal Therapeutics, Inc. reported Net Income of -$13.24 million for fiscal year 2025.
Cadrenal Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$13.24M | -24.3% |
| 2024 | -$10.65M | -27.5% |
| 2023 | -$8.36M | -24.5% |
| 2022 | -$6.71M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.69M | -11.5% | +26.8% |
| June 30, 2025 | -$3.67M | -53.3% | +4.6% |
| March 31, 2025 | -$3.85M | -131.2% | -59.7% |
| September 30, 2024 | -$2.41M | -132.3% | -0.6% |
| June 30, 2024 | -$2.39M | -138.6% | -43.9% |
| March 31, 2024 | -$1.66M | +67.9% | -60.5% |
| September 30, 2023 | -$1.04M | -1.0% | -3.3% |
| June 30, 2023 | -$1.00M | -99.7% | +80.6% |
- Cadrenal Therapeutics, Inc. showed a decrease of -24.3% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Cadrenal Therapeutics, Inc.’s net income has declined by 97.2% (from -$6.71 million to -$13.24 million).
- The most recent figure is from Cadrenal Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: